Oncology

Latest News

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com
Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

June 13th 2025

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg
Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

June 12th 2025

AJMC
Utilization and Costs Among Oncologists Participating in a Private Insurance Shared Savings Model

June 11th 2025

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com
C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

June 7th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Site Logo
September 4th 2017

Consistent Use of E-Cigarettes Can Help Smoking Cessation

AJMC Staff
According to a study published in The BMJ, while e-cigarettes can assist smokers to quit, the number of days of e-cigarette use will determine quit attempt and quit success.
Site Logo
September 4th 2017

Healthy, but Still Hurting: Challenges of Cancer Survivorship

Laura Joszt, MA
The assumption in the United States is that once someone with cancer is cured, done with treatment, and healthy, that they are now okay. However, the reality is that survivors contend with lingering challenges that aren’t visible and make it difficult for them to ask for help or admit they need it.
Dr Kashyap Patel Discusses Implementing the Oncology Care Model
September 4th 2017

Dr Kashyap Patel Discusses Implementing the Oncology Care Model

Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, explains how previous experience with alternative payment models helped a smooth transition into the Oncology Care Model (OCM).
Podcast: This Week in Managed Care - Hurricane Relief Efforts, and Other Health News
September 3rd 2017

Podcast: This Week in Managed Care - Hurricane Relief Efforts, and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Site Logo
September 1st 2017

A New Treatment Option for Newly Diagnosed AML: Gemtuzumab Ozogamicin

AJMC Staff
The treatment, which was approved nearly 2 decades ago but withdrawn due to safety and efficacy concerns, now has a new indication.
Dr Charlie Fazio on Balancing Different Delivery and Payment Models
September 1st 2017

Dr Charlie Fazio on Balancing Different Delivery and Payment Models

Charlie Fazio, MD, senior vice president and medical director of HealthPartners discusses how to balance different payment models in order to understand their impacts on cost and patient outcomes when they are implemented.
Site Logo
September 1st 2017

5 Significant Developments With CAR-T Therapy

Surabhi Dangi-Garimella, PhD
A look at some of the major developments in the chimeric antigen receptor T (CAR-T) cell space.
This Week in Managed Care: September 1, 2017
September 1st 2017

This Week in Managed Care: September 1, 2017

This week, the top managed care stories included responses to the disaster in Houston after Hurricane Harvey; the approval of the first gene therapy in the United States; and a new cardiovascular indication for a popular drug to treat type 2 diabetes.
Site Logo
September 1st 2017

FDA Emphasizes Risks of Pembrolizumab in Multiple Myeloma After Reviewing Halted Trials

Christina Mattina
Less than 2 months after it ordered a stop to 3 trials of pembrolizumab (Keytruda) in multiple myeloma due to safety concerns, the FDA has released a more detailed analysis of what went wrong in these trials.
Site Logo
August 31st 2017

Pembrolizumab Plus Epacadostat Yields Durable Response in Advanced Melanoma: ESMO

Surabhi Dangi-Garimella, PhD
Results of a combination trial evaluating epacadostat with pembrolizumab in advanced melanoma, to be presented at the upcoming European Society for Medical Oncology (ESMO) 2017 Congress, has found that the treatment is well tolerated and has promising clinical activity.
Site Logo
August 30th 2017

Race, Socioeconomic Status Linked to Rehospitalizations Among Patients With Advanced Cancer

Christina Mattina
A new study finds that individuals with advanced cancer have high rates of hospitalization in the year after diagnosis. Palliative care aimed at preventing hospital admissions may be a useful tool, especially for the populations most at risk of rehospitalization.
Site Logo
August 30th 2017

FDA Approves Tisagenlecleucel, the First CAR-T Cell Therapy in the United States

Laura Joszt, MA
The FDA has approved the first chimeric antigen receptor-T (CAR-T) treatment, tisagenlecleucel (Kymriah), for the treatment of B-cell precursor acute lymphoblastic leukemia in certain pediatric and young adult patients. The therapy represents a new frontier in cancer care.
Site Logo
August 29th 2017

FDA Approves Expanded Use of Fulvestrant as First-Line Hormonal Breast Cancer Therapy

Christina Mattina
AstraZeneca announced that the FDA has expanded the indications for fulvestrant (Faslodex). The drug is now approved as first-line monotherapy for women with certain types of breast cancer.
Site Logo
August 28th 2017

Ancestry Determines Effective and Harmful Dose in Breast Cancer

Surabhi Dangi-Garimella, PhD
A study published in JCO Precision Oncology has identified an association between genetic inheritance and patients’ response to efficacy and toxicity in the phase 3 ECOG-ACRIN-5103 trial.
Site Logo
August 25th 2017

Case Study Identifies New Trigger for CAR-T Cell Expansion in DLBCL in JCAR017 Trial

Surabhi Dangi-Garimella, PhD
Chimeric antigen receptor (CAR)-T cells can re-expand in a lymphoma patient months after the initial infusion and can also be active against the patient’s cancer, according to a new study.
Site Logo
August 25th 2017

High-Dose Vitamin B Supplements Linked to Lung Cancer Risk in Men, Particularly Smokers

Christina Mattina
A new study points to an association between use of high-dose vitamin B6 and B12 supplements and an increased risk of lung cancer in men, especially in those who smoke.
Site Logo
August 24th 2017

Study Finds HPV Vaccination Underutilized by Childhood Cancer Survivors

Surabhi Dangi-Garimella, PhD
A new study in the Journal of Clinical Oncology identifies an increased role for physicians in boosting human papillomavirus (HPV) vaccination rates among childhood cancer survivors to reduce their risk of a second cancer.
Site Logo
August 23rd 2017

End-of-Life Palliative Care Lowered Utilization for Patients With Cancer

Christina Mattina
A new study indicates that palliative care can significantly reduce end-of-life hospitalizations and aggressive procedures among Medicare beneficiaries with advanced cancer.
Site Logo
August 23rd 2017

What Is the Ideal Age for Screening Mammography?

Surabhi Dangi-Garimella, PhD
According to a new study published in Cancer, an annual screening mammogram starting at age 40 has the greatest impact on reducing mortality.
Site Logo
August 21st 2017

Financial Concerns Influence Care-Seeking Behavior of Childhood Cancer Survivors

Surabhi Dangi-Garimella, PhD
High out-of-pocket (OOP) medical costs in survivors of childhood cancer can influence their treatment choices and care-related behavior, and ultimately affect their health outcomes, according to a study published in the Journal of Clinical Oncology.
Site Logo
August 21st 2017

FDA Approves Besponsa for Relapsed/Refractory Acute Lymphoblastic Leukemia

Alison Rodriguez
The FDA has approved Besponsa (inotuzumab ozogamicin) for treating adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Site Logo
August 18th 2017

Phase 1 Trial Indicates Pembrolizumab Safe in Aggressive Small-Cell Lung Cancer

Christina Mattina
A small phase 1b trial of pembrolizumab in patients with small-cell lung cancer shows that the immunotherapy drug had a favorable safety profile and demonstrated “promising” antitumor activity.
Site Logo
August 17th 2017

Noninvasive ctDNA Test Sensitive to Early-Stage Cancer

Surabhi Dangi-Garimella, PhD
Researchers from the United States, Netherlands, and Denmark have collaborated on developing a new liquid biopsy test that can detect circulating cell-free DNA in patients with early-stage cancer.
Site Logo
August 16th 2017

Small Study Confirms Feasibility of a Personalized Neoantigen Vaccine for Melanoma

Surabhi Dangi-Garimella, PhD
A new study, published in the journal Nature, has confirmed the efficacy of a melanoma vaccine targeted against 20 predicted personal tumor neoantigens in 6 patients.
Site Logo
August 16th 2017

Persistent Neuropathy After Chemotherapy Leads to Falls, Disability in Women

Christina Mattina
Following completion of their chemotherapy regimen, many women who have survived cancer experience lingering symptoms of chemotherapy-induced peripheral neuropathy, according to a new study.
Site Logo
August 15th 2017

Cancer Drug Price Increases Cost Medicaid Millions in Extra Spending, Analysis Shows

Christina Mattina
An analysis by Kaiser Health News found that Medicaid incurred billions of dollars in extra spending as a result of price increases for hundreds of common drugs from 2015 to 2016, including decades-old branded drugs and generics used to treat cancer.
Site Logo
August 15th 2017

Short-Term CV Risk in Patients With Newly Diagnosed Cancer

Surabhi Dangi-Garimella, PhD
A retrospective study in patients with newly diagnosed cancer has identified an increased risk of cardiovascular (CV) abnormalities that are aggravated by cancer stage.
Dr Lee Newcomer on UnitedHealthcare's Value-Based Contracts
August 15th 2017

Dr Lee Newcomer on UnitedHealthcare's Value-Based Contracts

UnitedHealth is currently involved in 2 types of value-based contracts with its provider partners, but it has seen more success with one compared with the other, explained Lee N. Newcomer, MD, MHA, senior vice president of oncology and genetics at UnitedHealthcare.
Site Logo
August 14th 2017

The American Journal of Managed Care® to Host the 2017 Patient-Centered Oncology Care® Meeting

This meeting presents unique perspectives on emerging topics in managed care from today’s leading experts
Site Logo
August 14th 2017

Targeted Therapies: One Practice's Story

Barry Kaplan, MD, PhD
A community oncologist's perspective on the advantages and challenges with precision medicine.
<1
...
676869707172737475
...
186>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo